Search

Your search keyword '"Cloughesy, T."' showing total 366 results
Start Over Author "Cloughesy, T."
366 results on '"Cloughesy, T."'

1. Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.

Author

Sahebjam, S, Kim, H, Harris, R, Woodworth, D, Lai, A, Mason, W, Cloughesy, T, Pope, Whitney, Ellingson, Benjamin, and Nghiemphu, Phioanh

Subjects
Aged, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Bevacizumab, Brain Neoplasms, Diffusion Magnetic Resonance Imaging, Disease Progression, Disease-Free Survival, Drug Monitoring, Glioblastoma, Humans, Middle Aged, Neoplasm Recurrence, Local, Predictive Value of Tests, Proportional Hazards Models, Retrospective Studies
Abstract

BACKGROUND AND PURPOSE: Pre-treatment ADC characteristics have been shown to predict response to bevacizumab in recurrent glioblastoma multiforme. However, no studies have examined whether ADC characteristics are specific to this particular treatment. The purpose of the current study was to determine whether ADC histogram analysis is a bevacizumab-specific or treatment-independent biomarker of treatment response in recurrent glioblastoma multiforme. MATERIALS AND METHODS: Eighty-nine bevacizumab-treated and 43 chemotherapy-treated recurrent glioblastoma multiformes never exposed to bevacizumab were included in this study. In all patients, ADC values in contrast-enhancing ROIs from MR imaging examinations performed at the time of recurrence, immediately before commencement of treatment for recurrence, were extracted and the resulting histogram was fitted to a mixed model with a double Gaussian distribution. Mean ADC in the lower Gaussian curve was used as the primary biomarker of interest. The Cox proportional hazards model and log-rank tests were used for survival analysis. RESULTS: Cox multivariate regression analysis accounting for the interaction between bevacizumab- and non-bevacizumab-treated patients suggested that the ability of the lower Gaussian curve to predict survival is dependent on treatment (progression-free survival, P = .045; overall survival, P = .003). Patients with bevacizumab-treated recurrent glioblastoma multiforme with a pretreatment lower Gaussian curve > 1.2 μm(2)/ms had a significantly longer progression-free survival and overall survival compared with bevacizumab-treated patients with a lower Gaussian curve < 1.2 μm(2)/ms. No differences in progression-free survival or overall survival were observed in the chemotherapy-treated cohort. Bevacizumab-treated patients with a mean lower Gaussian curve > 1.2 μm(2)/ms had a significantly longer progression-free survival and overall survival compared with chemotherapy-treated patients. CONCLUSIONS: The mean lower Gaussian curve from ADC histogram analysis is a predictive imaging biomarker for bevacizumab-treated, not chemotherapy-treated, recurrent glioblastoma multiforme. Patients with recurrent glioblastoma multiforme with a mean lower Gaussian curve > 1.2 μm(2)/ms have a survival advantage when treated with bevacizumab.

Published
2014

2. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy

Author

Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein Jr G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, and Bendell JC

Subjects
cc-115, mtorc1/mtorc2, mtor inhibitor, dna-pk inhibitor, phase i study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Pamela Munster,1 Monica Mita,2 Amit Mahipal,3 John Nemunaitis,4 Christophe Massard,5 Tom Mikkelsen,6 Cristina Cruz,7 Luis Paz-Ares,8 Manuel Hidalgo,9 Dana Rathkopf,10 George Blumenschein Jr,11 David C Smith,12 Barbara Eichhorst,13 Tim Cloughesy,14 Ellen H Filvaroff,15 Shaoyi Li,16 Heather Raymon,17 Hans de Haan,15 Kristen Hege,15 Johanna C Bendell18 1UCSF Helen Diller Family Comprehensive Cancer Center, Department of Medicine, San Francisco, CA, USA; 2Samuel Oschin Comprehensive Cancer Institute, Internal Medicine Medical Oncology Department, Los Angeles, CA, USA; 3Mayo Clinic, Medical Oncology Department, Rochester, MN, USA; 4University of Toledo College of Medicine and Life Sciences, Hematology/Oncology Department, Toledo, OH, USA; 5Institut Gustave Roussy, Drug Development Department, Paris, France; 6Henry Ford Health System, Neurology Department, Detroit, MI, USA; 7Vall d’Hebron University Hospital, Medical Oncology Department, Barcelona, Spain; 8University Hospital 12 de Octubre, CNIO, Universidad Complutense & Ciberonc, Medical Oncology Department, Madrid, Spain; 9Centro Integral Oncológico Clara Campal, Oncology Department, Madrid, Spain; 10Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY, USA; 11The University of Texas MD Anderson Cancer Center, Department of Thoracic/Head and Neck Medical Oncology, Houston, TX, USA; 12University of Michigan, Urology Oncology, Ann Arbor, MI, USA; 13University Hospital of Cologne, Department I for Internal Medicine, Cologne, Germany; 14David Geffen School of Medicine, Neurology Department, UCLA, Los Angeles, CA, USA; 15Celgene Corporation, Translational Development Department, San Francisco, CA, USA; 16Celgene Corporation, Department of Statistics, Summit, NJ, USA; 17Celgene Corporation, Department of Pharmacology, San Diego, CA, USA; 18Sarah Cannon Research Institute, Drug Development Unit, Tennessee Oncology, Nashville, TN, USACorrespondence: Johanna C BendellSarah Cannon Research Institute, Drug Development Unit, Tennessee Oncology, 250 25th Ave North, Suite 110, Nashville, TN 37203, USATel +1 615 329 7274Email jbendell@tnonc.comPurpose: This first-in-human Phase I study investigated the safety, pharmacokinetics (PK), pharmacodynamic profile, and preliminary efficacy of CC-115, a dual inhibitor of mammalian target of rapamycin (mTOR) kinase and DNA-dependent protein kinase.Patients and Methods: Patients with advanced solid or hematologic malignancies were enrolled in dose-finding and cohort expansion phases. In dose-finding, once-daily or twice-daily (BID) ascending oral doses of CC-115 (range: 0.5–40 mg/day) in 28-day continuous cycles identified the maximum-tolerated dose for cohort expansion in 5 specified tumor types. Twelve additional patients with mixed solid tumors participated in a bioavailability substudy.Results: Forty-four patients were enrolled in the dose-finding cohort. Dose-limiting toxicity included thrombocytopenia, stomatitis, hyperglycemia, asthenia/fatigue, and increased transaminases. CC-115 10 mg BID was selected for cohort expansion (n=74) in which fatigue, nausea, and decreased appetite were the most frequent toxicities. Dose-proportional PK was found. CC-115 distributed to glioblastoma tissue (mean tumor/plasma concentration ratio: 0.713). Total exposure of CC-115 was similar under fasting and fed conditions. A patient with endometrial carcinoma remained in complete remission >4 years. Partial response (PR; n=2) and stable disease (SD; n=4) were reported in the bioavailability substudy; SD was reached in 53%, 22%, 21%, and 64% of patients with head and neck squamous cell carcinoma, Ewing sarcoma, glioblastoma multiforme, and castration-resistant prostate cancer, respectively. Chronic lymphocytic leukemia/small lymphocytic lymphoma showed 38% PR and 25% SD.Conclusion: CC-115 was well-tolerated, with toxicities consistent with mTOR inhibitors. Together with biomarker inhibition and preliminary efficacy, oral CC-115 10 mg BID is a promising novel anticancer treatment.Clinical trial registration: NCT01353625.Keywords: CC-115, mTORC1/mTORC2, mTOR inhibitor, DNA-PK inhibitor, Phase I study

Published
2019

5. P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma

Author

Weller, M, primary, Ellingson, B, additional, Alexander, B, additional, Wen, P, additional, Sulman, E, additional, Colman, H, additional, Berry, D, additional, Tanner, K, additional, Khasraw, M, additional, Lim, M, additional, Perry, J, additional, Lassman, A, additional, Cloughesy, T, additional, Yung, W K A, additional, Lee, E Q, additional, Mellinghoff, I, additional, Gordon, G, additional, de Groot, J, additional, Mikkelsen, T, additional, Cavenee, W, additional, Nelli, A, additional, Buxton, M, additional, and Li, W, additional

Published
2022
Full Text
View/download PDF

7. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial

Author

Omuro, A, Brandes, AA, Carpentier, AF, Idbaih, A, Reardon, DA, Cloughesy, T, Sumrall, A, Baehring, J, van den Bent, M, Bähr, O, Lombardi, G, Mulholland, P, Tabatabai, G, Lassen, U, Sepulveda, JM, Khasraw, Mustafa, Vauleon, E, Muragaki, Y, Di Giacomo, AM, Butowski, N, Roth, P, Qian, X, Fu, AZ, Liu, Y, Potter, V, Chalamandaris, A-G, Tatsuoka, K, Lim, M, Weller, M, Omuro, A, Brandes, AA, Carpentier, AF, Idbaih, A, Reardon, DA, Cloughesy, T, Sumrall, A, Baehring, J, van den Bent, M, Bähr, O, Lombardi, G, Mulholland, P, Tabatabai, G, Lassen, U, Sepulveda, JM, Khasraw, Mustafa, Vauleon, E, Muragaki, Y, Di Giacomo, AM, Butowski, N, Roth, P, Qian, X, Fu, AZ, Liu, Y, Potter, V, Chalamandaris, A-G, Tatsuoka, K, Lim, M, and Weller, M

Abstract

Abstract Background Addition of temozolomide (TMZ) to radiotherapy (RT) improves overall survival (OS) in patients with glioblastoma (GBM), but previous studies suggest that patients with tumors harboring an unmethylated MGMT promoter derive minimal benefit. The aim of this open-label, phase III CheckMate 498 study was to evaluate the efficacy of nivolumab (NIVO) + RT compared with TMZ + RT in newly diagnosed GBM with unmethylated MGMT promoter. Methods Patients were randomized 1:1 to standard RT (60 Gy) + NIVO (240 mg every 2 weeks for eight cycles, then 480 mg every 4 weeks) or RT + TMZ (75 mg/m2 daily during RT and 150–200 mg/m2/day 5/28 days during maintenance). The primary endpoint was OS. Results A total of 560 patients were randomized, 280 to each arm. Median OS (mOS) was 13.4 months (95% CI, 12.6 to 14.3) with NIVO + RT and 14.9 months (95% CI, 13.3 to 16.1) with TMZ + RT (hazard ratio [HR], 1.31; 95% CI, 1.09 to 1.58; P = .0037). Median progression-free survival was 6.0 months (95% CI, 5.7 to 6.2) with NIVO + RT and 6.2 months (95% CI, 5.9 to 6.7) with TMZ + RT (HR, 1.38; 95% CI, 1.15 to 1.65). Response rates were 7.8% (9/116) with NIVO + RT and 7.2% (8/111) with TMZ + RT; grade 3/4 treatment-related adverse event (TRAE) rates were 21.9% and 25.1%, and any-grade serious TRAE rates were 17.3% and 7.6%, respectively. Conclusions The study did not meet the primary endpoint of improved OS; TMZ + RT demonstrated a longer mOS than NIVO + RT. No new safety signals were detected with NIVO in this study. The difference between the study treatment arms is consistent with the use of TMZ + RT as the standard of care for GBM. ClinicalTrials.gov NCT02617589

Published
2022

12. A modeling-based factor extraction method for determining spatial heterogeneity of a Ga-68 EDTA kinetics in brain tumors

Author

Zhou, Yun, Huang, S.C., Cloughesy, T., Hoh, C.K., Black, K., and Phelps, M.E.

Subjects
Brain tumors -- Analysis, Ethylenediaminetetraacetic acid -- Analysis, PET imaging -- Usage, Business, Electronics, Electronics and electrical industries
Abstract

The ROI method applied to Ga-68 EDTA PET dynamic study data for the quantitative determination of brain tumor BBB permeability assumes that the tumor is homogeneous in terms of Ga-68 EDTA kinetics, even though it is known that brain tumors are highly heterogeneous in structure. The relatively high image noise of Ga-68 PET studies have prevented the examination of Ga-68 EDTA kinetics by nonlinear regression on a single pixel basis. In this study, we have developed an efficient and effective method to separate brain tumor tissue into sub-regions with different Ga-68 EDTA kinetics on a pixel-by-pixel basis. Computer simulation and ten Ga-68 EDTA PET patient studies were used to evaluate the performance of the new method. During a PET dynamic study (total 64 min), 20 - 25 arterial samples were taken for the input function. Whole-tumor ROIs were defined on T1-weighted MRI images and then copied to the registered PET dynamic images to measure whole-tumor time activity curves. The method uses a two-compartment model to extract three component factors (vascular component, fast and slow component factors) from whole-tumor kinetics by model fitting. The kinetics in each pixel were expressed as a linear combination of the three factors. The three coefficients in the expression can be estimated by the linear least-square method and produce three factor images corresponding, respectively, to the permeability of the fast and the slow component factors and the plasma volume. Whole-tumor regions were separated into two regions - one with mainly fast kinetics that was evident in the fast factor images and one with slow kinetics that was evident in slow factor images. The two regions have markedly different uptake (0.036 [+ or -] 0.015 ml/min/g and 0.009 [+ or -] 0.006 ml/min/g for fast and slow kinetic sub-regions, respectively) and clearance rates (0.22 [+ or -] 0.15 /min and 0.023 [+ or -] 0.021 /min for fast and slow sub-regions, respectively). The overlap of the two resulting sub-regions is small (3.5 [+ or -] 1.7% of the two regions). Computer simulation and patient studies show that the method is robust for a wide range of noise levels. This method has combined the advantages of statistical factor analysis and the modeling approach.

Published
1997

15. OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study

Author

Lassman, A B, primary, Sepúlveda-Sánchez, J M, additional, Cloughesy, T, additional, Gil-Gil, J M, additional, Puduvalli, V K, additional, Raizer, J, additional, De Vos, F Y, additional, Wen, P Y, additional, Butowski, N, additional, Clement, P, additional, Groves, M D, additional, Belda-Iniesta, C, additional, Steward, K, additional, Moran, S, additional, Ye, Y, additional, and Roth, P, additional

Published
2019
Full Text
View/download PDF

18. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment

Author

Kong, X., Nguyen, N., Choi, Y., Zhang, Guicheng, Nguyen, H., Filka, E., Green, S., Yong, W., Liau, L., Green, R., Kaprealian, T., Pope, W., Nghiemphu, P., Cloughesy, T., Lassman, A., Lai, A., Kong, X., Nguyen, N., Choi, Y., Zhang, Guicheng, Nguyen, H., Filka, E., Green, S., Yong, W., Liau, L., Green, R., Kaprealian, T., Pope, W., Nghiemphu, P., Cloughesy, T., Lassman, A., and Lai, A.

Abstract

© 2018 Elsevier Inc. Purpose: To assess the safety and efficacy of upfront treatment using bortezomib combined with standard radiation therapy (RT) and temozolomide (TMZ), followed by adjuvant bortezomib and TMZ for =24 cycles, in patients with newly diagnosed glioblastoma multiforme (GBM). Methods and Materials: Twenty-four patients with newly diagnosed GBM were enrolled. The patients received standard external beam regional RT with concurrent TMZ beginning 3 to 6 weeks after surgery, followed by adjuvant TMZ and bortezomib for =24 cycles or until tumor progression. During RT, bortezomib was given at 1.3 mg/m2 on days 1, 4, 8, 11, 29, 32, 36, and 39. After RT, bortezomib was given at 1.3 mg/m2 on days 1, 4, 8, and 11 every 4 weeks. Results: No unexpected adverse events occurred from the addition of bortezomib. The efficacy analysis showed a median progression-free survival (PFS) of 6.2 months (95% confidence interval [CI] 3.7-8.8), with promising PFS rates at =18 months compared with historical norms (25.0% at 18 and 24 months; 16.7% at 30 months). In terms of overall survival (OS), the median OS was 19.1 months (95% CI 6.7-31.4), with improved OS rates at =12 months (87.5% at 12, 50.0% at 24, 34.1% at 36-60 months) compared with the historical norms. The median PFS was 24.7 months (95% CI 8.5-41.0) in 10 MGMT methylated and 5.1 months (95% CI 3.9-6.2) in 13 unmethylated patients. The estimated median OS was 61 months (95% CI upper bound not reached) in the methylated and 16.4 months (95% CI 11.8-21.0) in the unmethylated patients. Conclusions: The addition of bortezomib to current standard radiochemotherapy in newly diagnosed GBM patients was tolerable. The PFS and OS rates appeared promising, with more benefit to MGMT methylated patients. Further clinical investigation is warranted in a larger cohort of patients.

Published
2018

19. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses

Author

Cloughesy, T, Finocchiaro, G, Belda-Iniesta, C, Recht, L, Brandes, AA, Pineda, E, Mikkelsen, T, Chinot, OL, Balana, C, Macdonald, DR, Westphal, M, Hopkins, K, Weller, M, Bais, C, Sandmann, T, Bruey, JM, Koeppen, H, Liu, B, Verret, W, Phan, SC, Shames, DS, University of Zurich, and Cloughesy, Timothy

Subjects
610 Medicine & health, 2730 Oncology, 1306 Cancer Research, 10040 Clinic for Neurology
Abstract

Purpose Bevacizumab regimens are approved for the treatment of recurrent glioblastoma in many countries. Aberrant mesenchymal-epithelial transition factor (MET) expression has been reported in glioblastoma and may contribute to bevacizumab resistance. The phase II study GO27819 investigated the monovalent MET inhibitor onartuzumab plus bevacizumab (Ona + Bev) versus placebo plus bevacizumab (Pla + Bev) in recurrent glioblastoma. Methods At first recurrence after chemoradiation, bevacizumab-naive patients with glioblastoma were randomly assigned 1: 1 to receive Ona (15 mg/kg, once every 3 weeks) + Bev (15 mg/kg, once every 3 weeks) or Pla + Bev until disease progression. The primary end point was progression-free survival by response assessment in neuro-oncology criteria. Secondary end points were overall survival, objective response rate, duration of response, and safety. Exploratory biomarker analyses correlated efficacy with expression levels of MET ligand hepatocyte growth factor, O-6-methylguanine-DNA methyltransferase promoter methylation, and glioblastoma subtype. Results Among 129 patients enrolled (Ona + Bev, n = 64; Pla + Bev, n = 65), baseline characteristics were balanced. The median progression-free survival was 3.9 months for Ona + Bev versus 2.9 months for Pla + Bev (hazard ratio, 1.06; 95% CI, 0.72 to 1.56; P = .7444). The median overall survival was 8.8 months for Ona + Bev and 12.6 months for Pla + Bev (hazard ratio, 1.45; 95% CI, 0.88 to 2.37; P = .1389). Grade >= 3 adverse events were reported in 38.5% of patients who received Ona + Bev and 35.9% of patients who received Pla + Bev. Exploratory biomarker analyses suggested that patients with high expression of hepatocyte growth factor or unmethylated O-6-methylguanine-DNA methyltransferase may benefit from Ona + Bev. Conclusion There was no evidence of further clinical benefit with the addition of onartuzumab to bevacizumab compared with bevacizumab plus placebo in unselected patients with recurrent glioblastoma in this phase II study; however, further investigation into biomarker subgroups is warranted. (C) 2016 by American Society of Clinical Oncology

Published
2017
Full Text
View/download PDF

23. Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)

Author

Lim, M., primary, Omuro, A., additional, Vlahovic, G., additional, Reardon, D.A., additional, Sahebjam, S., additional, Cloughesy, T., additional, Baehring, J., additional, Butowski, N., additional, Potter, V., additional, Zwirtes, R., additional, Paliwal, P., additional, Carleton, M., additional, Sampson, J., additional, and Brandes, A.A., additional

Published
2017
Full Text
View/download PDF

27. Reply to F. Felix et al and M.F. Fay et al

Author

Happold, C, Gorlia, T, Chinot, O, Gilbert, M R, Nabors, L B, Wick, W, Pugh, S L, Hegi, M, Cloughesy, T, Roth, P, Reardon, D A, Perry, J R, Mehta, M P, Stupp, R, Weller, M, Happold, C, Gorlia, T, Chinot, O, Gilbert, M R, Nabors, L B, Wick, W, Pugh, S L, Hegi, M, Cloughesy, T, Roth, P, Reardon, D A, Perry, J R, Mehta, M P, Stupp, R, and Weller, M

Published
2016

31. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Author

Ellingson, B M, Bendszus, M, Boxerman, J, Barboriak, D, Erickson, B J, Smits, M, Nelson, S J, Gerstner, E, Alexander, B, Goldmacher, G, Wick, W, Vogelbaum, M, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, L, Jacobs, P, Pope, W B, Yang, D, Chung, C, Knopp, M V, Cha, S, van den Bent, M J, Chang, S, Al Yung, W K, Cloughesy, T F, Wen, P Y, Gilbert, M R, Ellingson, B M, Bendszus, M, Boxerman, J, Barboriak, D, Erickson, B J, Smits, M, Nelson, S J, Gerstner, E, Alexander, B, Goldmacher, G, Wick, W, Vogelbaum, M, Weller, M, Galanis, E, Kalpathy-Cramer, J, Shankar, L, Jacobs, P, Pope, W B, Yang, D, Chung, C, Knopp, M V, Cha, S, van den Bent, M J, Chang, S, Al Yung, W K, Cloughesy, T F, Wen, P Y, and Gilbert, M R

Abstract

A recent joint meeting was held on January 30, 2014, with the US Food and Drug Administration (FDA), National Cancer Institute (NCI), clinical scientists, imaging experts, pharmaceutical and biotech companies, clinical trials cooperative groups, and patient advocate groups to discuss imaging endpoints for clinical trials in glioblastoma. This workshop developed a set of priorities and action items including the creation of a standardized MRI protocol for multicenter studies. The current document outlines consensus recommendations for a standardized Brain Tumor Imaging Protocol (BTIP), along with the scientific and practical justifications for these recommendations, resulting from a series of discussions between various experts involved in aspects of neuro-oncology neuroimaging for clinical trials. The minimum recommended sequences include: (i) parameter-matched precontrast and postcontrast inversion recovery-prepared, isotropic 3D T1-weighted gradient-recalled echo; (ii) axial 2D T2-weighted turbo spin-echo acquired after contrast injection and before postcontrast 3D T1-weighted images to control timing of images after contrast administration; (iii) precontrast, axial 2D T2-weighted fluid-attenuated inversion recovery; and (iv) precontrast, axial 2D, 3-directional diffusion-weighted images. Recommended ranges of sequence parameters are provided for both 1.5 T and 3 T MR systems.

Published
2015

32. 26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma

Author

Happold, C., primary, Gorlia, T., additional, Chinot, O., additional, Gilbert, M., additional, Nabors, L.B., additional, Wick, W., additional, Pugh, S.L., additional, Hegi, M., additional, Cloughesy, T., additional, Roth, P., additional, Reardon, D.A., additional, Perry, J.R., additional, Mehta, M.P., additional, Stupp, R., additional, and Weller, M., additional

Published
2015
Full Text
View/download PDF

35. RADIOLOGY

Author

Bluml, S., primary, Panigrahy, A., additional, Laskov, M., additional, Dhall, G., additional, Nelson, M. D., additional, Finlay, J. L., additional, Gilles, F. H., additional, Arita, H., additional, Kinoshita, M., additional, Kagawa, N., additional, Fujimoto, Y., additional, Hashimoto, N., additional, Yoshimine, T., additional, Hamilton, J. D., additional, Wang, J., additional, Levin, V. A., additional, Hou, P., additional, Loghin, M. E., additional, Gilbert, M. R., additional, Leeds, N. E., additional, deGroot, J. F., additional, Puduvalli, V., additional, Jackson, E. F., additional, Yung, W. K. A., additional, Kumar, A. J., additional, Ellingson, B. M., additional, Cloughesy, T. F., additional, Pope, W. B., additional, Zaw, T., additional, Phillips, H., additional, Lalezari, S., additional, Nghiemphu, P. L., additional, Ibrahim, H., additional, Motevalibashinaeini, K., additional, Lai, A., additional, Harris, R., additional, Douw, L., additional, Van de Nieuwenhuijzen, M. E., additional, Heimans, J. J., additional, Baayen, J. C., additional, Stam, C. J., additional, Reijneveld, J. C., additional, Juhasz, C., additional, Mittal, S., additional, Altinok, D., additional, Robinette, N. L., additional, Muzik, O., additional, Chakraborty, P. K., additional, Barger, G. R., additional, Zaw, T. M., additional, Goldin, J., additional, Chen, W., additional, Ahlman, M. A., additional, Giglio, P., additional, Kaufmann, T. J., additional, Anderson, S. K., additional, Jaeckle, K. A., additional, Uhm, J. H., additional, Northfelt, D. W., additional, Flynn, P. J., additional, Buckner, J. C., additional, Galanis, E., additional, Zalatimo, O., additional, Weston, C., additional, Allison, D., additional, Bota, D., additional, Kesari, S., additional, Glantz, M., additional, Sheehan, J., additional, Harbaugh, R. E., additional, Chiba, Y., additional, Tsuboi, A., additional, Hatazawa, J., additional, Sugiyama, H., additional, Nariai, T., additional, Toyohara, J., additional, Tanaka, Y., additional, Inaji, M., additional, Aoyagi, M., additional, Yamamoto, M., additional, Ishiwara, K., additional, Ohno, K., additional, Jalilian, L., additional, Essock-Burns, E., additional, Cha, S., additional, Chang, S., additional, Prados, M., additional, Butowski, N., additional, Nelson, S., additional, Kawahara, Y., additional, Nakada, M., additional, Hayashi, Y., additional, Kai, Y., additional, Uchiyama, N., additional, Kuratsu, J.-i., additional, Hamada, J.-i., additional, Yeom, K., additional, Rosenberg, J., additional, Andre, J. B., additional, Fisher, P. G., additional, Edwards, M. S., additional, Barnes, P. D., additional, Partap, S., additional, Lupo, J. M., additional, Crane, J. C., additional, Chang, S. M., additional, Nelson, S. J., additional, Romanowski, C. A., additional, Hoggard, N., additional, Jellinek, D. A., additional, Clenton, S., additional, McKevitt, F., additional, Wharton, S., additional, Craven, I., additional, Buller, A., additional, Waddle, C., additional, Bigley, J., additional, Wilkinson, I. D., additional, Metherall, P., additional, Eckel, L. J., additional, Keating, G. F., additional, Wetjen, N. M., additional, Giannini, C., additional, Wetmore, C., additional, Jain, R., additional, Narang, J., additional, Arbab, A. S., additional, Schultz, L., additional, Scarpace, L., additional, Mikkelsen, T., additional, Babajni-Feremi, A., additional, Poisson, L., additional, Gutman, D., additional, Jaffe, C., additional, Saltz, J., additional, Flanders, A., additional, Daniel, B., additional, Zach, L., additional, Guez, D., additional, Last, D., additional, Daniels, D., additional, Hoffman, C., additional, Mardor, Y., additional, Guha-Thakurta, N., additional, Debnam, J. M., additional, Kotsarini, C., additional, Jellinek, D., additional, Griffiths, P. D., additional, Khandanpour, N., additional, Bambrough, P., additional, Prabhu, S., additional, Bassett, R. L., additional, Yung, W. A., additional, Campen, C. J., additional, Soman, S., additional, Yeom, K. W., additional, Vos, M. J., additional, Berkhof, J., additional, Postma, T. J., additional, Sanchez, E., additional, Sizoo, E. M., additional, Lagerwaard, F. J., additional, Buter, J., additional, Noske, D. P., additional, Colen, R. R., additional, Mahajan, B., additional, Jolesz, F. A., additional, Zinn, P. O., additional, Molinaro, A., additional, Lawton, K., additional, Alexandru, D., additional, Linskey, M. E., additional, Chaumeil, M. M., additional, Gini, B., additional, Yang, H., additional, Iwanami, A., additional, Subramanian, S., additional, Ozawa, T., additional, Read, E. J., additional, Pieper, R. O., additional, Mischel, P., additional, James, C. D., additional, Ronen, S. M., additional, LaViolette, P. S., additional, Cochran, E., additional, Al-Gizawiy, M., additional, Connelly, J. M., additional, Malkin, M. G., additional, Rand, S. D., additional, Mueller, W. M., additional, Schmainda, K. M., additional, Cohen, A. D., additional, Prah, M., additional, Hartman, C. J., additional, Qiao, X. J., additional, He, R., additional, Brown, M., additional, and Cloughesy, T., additional

Published
2011
Full Text
View/download PDF

36. MEDICAL AND NEURO-ONCOLOGY

Author

Prithviraj, G. K., primary, Sommers, S. R., additional, Jump, R. L., additional, Halmos, B., additional, Chambless, L. B., additional, Parker, S. L., additional, Hassam-Malani, L., additional, McGirt, M. J., additional, Thompson, R. C., additional, Hunter, K., additional, Chamberlain, M. C., additional, Le, E. M., additional, Lee, E. L. T., additional, Sadighi, Z. S., additional, Pearlman, M. L., additional, Slopis, J. M., additional, Vats, T. S., additional, Khatua, S., additional, DeVito, N. C., additional, Yu, M., additional, Chen, R., additional, Pan, E., additional, Cloughesy, T., additional, Raizer, J., additional, Drappatz, J., additional, Gerena-Lewis, M., additional, Rogerio, J., additional, Yacoub, S., additional, Desjardin, A., additional, Groves, M. D., additional, DeGroot, J., additional, Loghin, M., additional, Conrad, C. A., additional, Hess, K., additional, Ni, J., additional, Ictech, S., additional, Yung, W. A., additional, Porter, A. B., additional, Dueck, A. C., additional, Karlin, N. J., additional, Olson, J., additional, Silber, J., additional, Reiner, A. S., additional, Panageas, K. S., additional, Iwamoto, F. M., additional, Cloughesy, T. F., additional, Aldape, K. D., additional, Rivera, A. L., additional, Eichler, A. F., additional, Louis, D. N., additional, Paleologos, N. A., additional, Fisher, B. J., additional, Ashby, L. S., additional, Cairncross, J. G., additional, Roldan, G. B., additional, Wen, P. Y., additional, Ligon, K. L., additional, Shiff, D., additional, Robins, H. I., additional, Rocque, B. G., additional, Mason, W. P., additional, Weaver, S. A., additional, Green, R. M., additional, Kamar, F. G., additional, Abrey, L. E., additional, DeAngelis, L. M., additional, Jhanwar, S. C., additional, Rosenblum, M. K., additional, Lassman, A. B., additional, Cachia, D., additional, Alderson, L., additional, Moser, R., additional, Smith, T., additional, Yunus, S., additional, Saito, K., additional, Mukasa, A., additional, Narita, Y., additional, Tabei, Y., additional, Shinoura, N., additional, Shibui, S., additional, Saito, N., additional, Flechl, B., additional, Ackerl, M., additional, Sax, C., additional, Dieckmann, K., additional, Crevenna, R., additional, Widhalm, G., additional, Preusser, M., additional, Marosi, C., additional, Ay, C., additional, Dunkler, D., additional, Pabinger, I., additional, Zielinski, C., additional, Belongia, M., additional, Jogal, S., additional, Schlingensiepen, K.-H., additional, Bogdahn, U., additional, Stockhammer, G., additional, Mahapatra, A. K., additional, Venkataramana, N. K., additional, Oliushine, V., additional, Parfenov, V., additional, Poverennova, I., additional, Hau, P., additional, Jachimczak, P., additional, Heinrichs, H., additional, Mammoser, A. G., additional, Shonka, N. A., additional, de Groot, J. F., additional, Shibahara, I., additional, Sonoda, Y., additional, Kumabe, T., additional, Saito, R., additional, Kanamori, M., additional, Yamashita, Y., additional, Watanabe, M., additional, Ishioka, C., additional, Tominaga, T., additional, Silvani, A., additional, Gaviani, P., additional, Lamperti, E., additional, Botturi, A., additional, DiMeco, F., additional, Broggi, G., additional, Fariselli, L., additional, Solero, C. L., additional, Salmaggi, A., additional, Woyshner, E. A., additional, Shu, F., additional, Oh, Y. S., additional, Iganej, S., additional, Singh, G., additional, Vemuri, S. L., additional, Theeler, B. J., additional, Ellezam, B., additional, Gilbert, M. R., additional, Aoki, T., additional, Kobayashi, H., additional, Takano, S., additional, Nishikawa, R., additional, Nagane, M., additional, Muragaki, Y., additional, Sugiyama, K., additional, Kuratsu, J., additional, Matsutani, M., additional, Langford, L. A., additional, Puduvalli, V. K., additional, Shen, D., additional, Chen, Z.-p., additional, Zhang, J.-p., additional, Bedekar, D., additional, Rand, S., additional, Connelly, J., additional, Malkin, M., additional, Paulson, E., additional, Mueller, W., additional, Schmainda, K., additional, Gallego, O., additional, Benavides, M., additional, Segura, P. P., additional, Balana, C., additional, Gil, M., additional, Berrocal, A., additional, Reynes, G., additional, Garcia, J. L., additional, Murata, P., additional, Bague, S., additional, Quintana, M. J., additional, Vasishta, V. G., additional, Kobayashi, K., additional, Tanaka, M., additional, Tsuchiya, K., additional, Shiokawa, Y., additional, Bavle, A. A., additional, Ayyanar, K., additional, Prado, M. P., additional, Hess, K. R., additional, Liu, V., additional, de Groot, J., additional, Loghin, M. E., additional, Colman, H., additional, Levin, V. A., additional, Alfred Yung, W. K., additional, Hackney, J. R., additional, Palmer, C. A., additional, Markert, J. M., additional, Cure, J., additional, Riley, K. O., additional, Fathallah-Shaykh, H., additional, Nabors, L. B., additional, Saria, M. G., additional, Corle, C., additional, Hu, J., additional, Rudnick, J., additional, Phuphanich, S., additional, Mrugala, M. M., additional, Lee, L. K., additional, Fu, B. D., additional, Bota, D. A., additional, Kim, R. Y., additional, Brown, T., additional, Feely, H., additional, Hu, A., additional, Lee, J. W., additional, Carter, B., additional, Kesari, S., additional, Kong, X.-T., additional, Sparagana, S., additional, Belousova, E., additional, Jozwiak, S., additional, Korf, B., additional, Frost, M., additional, Kuperman, R., additional, Kohrman, M., additional, Witt, O., additional, Wu, J., additional, Flamini, R., additional, Jansen, A., additional, Curtalolo, P., additional, Thiele, E., additional, Whittemore, V., additional, De Vries, P., additional, Ford, J., additional, Shah, G., additional, Cauwel, H., additional, Edrich, P., additional, Sahmoud, T., additional, Franz, D., additional, Khasraw, M., additional, Brown, C., additional, Ashley, D. M., additional, Rosenthal, M. A., additional, Jiang, X., additional, Mou, Y. g., additional, Chen, Z. p., additional, Oh, M., additional, kim, E., additional, Chang, J., additional, Juratli, T. A., additional, Kirsch, M., additional, Schackert, G., additional, Krex, D., additional, Wang, M., additional, Stupp, R., additional, Hegi, M., additional, Jaeckle, K. A., additional, Armstrong, T. S., additional, Wefel, J. S., additional, Won, M., additional, Blumenthal, D. T., additional, Mahajan, A., additional, Schultz, C. J., additional, Erridge, S. C., additional, Brown, P. D., additional, Chakravarti, A., additional, Curran, W. J., additional, Mehta, M. P., additional, Hofland, K. F., additional, Hansen, S., additional, Sorensen, M., additional, Schultz, H., additional, Muhic, A., additional, Engelholm, S., additional, Ask, A., additional, Kristiansen, C., additional, Thomsen, C., additional, Poulsen, H. S., additional, Lassen, U. N., additional, Zalatimo, O., additional, Weston, C., additional, Zoccoli, C., additional, Glantz, M., additional, Rahmanuddin, S., additional, Shiroishi, M. S., additional, Cen, S. Y., additional, Jones, J., additional, Chen, T., additional, Pagnini, P., additional, Go, J., additional, Lerner, A., additional, Gomez, J., additional, Law, M., additional, Ram, Z., additional, Wong, E. T., additional, Gutin, P. H., additional, Bobola, M. S., additional, Alnoor, M., additional, Silbergeld, D. L., additional, Rostomily, R. C., additional, Silber, J. R., additional, Martha, N., additional, Jacqueline, S., additional, Thaddaus, G., additional, Daniel, P., additional, Hans, M., additional, Armin, M., additional, Eugen, T., additional, Gunther, S., additional, Hutterer, M., additional, Tseng, H.-M., additional, Zoccoli, C. M., additional, Patel, A., additional, Rizzo, K., additional, Sheehan, J. M., additional, Sumrall, A. L., additional, Vredenburgh, J. J., additional, Desjardins, A., additional, Reardon, D. A., additional, Friiedman, H. S., additional, Peters, K. B., additional, Taylor, L. P., additional, Stewart, M., additional, Blondin, N. A., additional, Baehring, J. M., additional, Foote, T., additional, Laack, N., additional, Call, J., additional, Hamilton, M. G., additional, Walling, S., additional, Eliasziw, M., additional, Easaw, J., additional, Shirsat, N. V., additional, Kundar, R., additional, Gokhale, A., additional, Goel, A., additional, Moiyadi, A. A., additional, Wang, J., additional, Mutlu, E., additional, Oyan, A., additional, Yan, T., additional, Tsinkalovsky, O., additional, Jacobsen, H. K., additional, Talasila, K. M., additional, Sleire, L., additional, Pettersen, K., additional, Miletic, H., additional, Andersen, S., additional, Mitra, S., additional, Weissman, I., additional, Li, X., additional, Kalland, K.-H., additional, Enger, P. O., additional, Sepulveda, J., additional, Belda, C., additional, Sitt, R., additional, Phishniak, L., additional, Bokstein, F., additional, Philippe, M., additional, Carole, C., additional, Andre, M. d. P., additional, Marylin, B., additional, Olivier, C., additional, L'Houcine, O., additional, Dominique, F.-B., additional, Isabelle, N.-M., additional, Frederic, F., additional, Stephane, F., additional, Henry, D., additional, Errico, M. A., additional, Kunschner, L. J., additional, Soffietti, R., additional, Trevisan, E., additional, Ruda, R., additional, Bertero, L., additional, Bosa, C., additional, Fabrini, M. G., additional, Lolli, I., additional, Jalali, R., additional, Julka, P. K., additional, Anand, A. K., additional, Bhavsar, D., additional, Singhal, N., additional, Naik, R., additional, John, S., additional, Mathew, B. S., additional, Thaipisuttikul, I., additional, Graber, J., additional, Shirinian, M., additional, Fontebasso, A. M., additional, Jacob, K., additional, Gerges, N., additional, Montpetit, A., additional, Nantel, A., additional, Albrecht, S., additional, Jabado, N., additional, Shah, K., additional, Di, K., additional, Linskey, M., additional, Thon, N., additional, Eigenbrod, S., additional, Kreth, S., additional, Lutz, J., additional, Tonn, J.-C., additional, Kretzschmar, H., additional, Peraud, A., additional, Kreth, F.-W., additional, Muggeri, A. D., additional, Alderuccio, J. P., additional, Diez, B. D., additional, Jiang, P., additional, Chao, Y., additional, Gallagher, M., additional, Kim, R., additional, Pastorino, S., additional, Fogal, V., additional, Rudnick, J. D., additional, Bresee, C., additional, Rogatko, A., additional, Sakowsky, S., additional, Franco, M., additional, Lim, S., additional, Lopez, A., additional, Yu, L., additional, Ryback, K., additional, Tsang, V., additional, Lill, M., additional, Steinberg, A., additional, Sheth, R., additional, Grimm, S., additional, Helenowski, I., additional, Rademaker, A., additional, Nunes, F. P., additional, Merker, V., additional, Jennings, D., additional, Caruso, P., additional, Muzikansky, A., additional, Stemmer-Rachamimov, A., additional, Plotkin, S., additional, Spalding, A. C., additional, Vitaz, T. W., additional, Sun, D. A., additional, Parsons, S., additional, Welch, M. R., additional, Omuro, A., additional, Beal, K., additional, Correa, D., additional, Chan, T., additional, DeAngelis, L., additional, Gavrilovic, I., additional, Nolan, C., additional, Hormigo, A., additional, Kaley, T., additional, Mellinghoff, I., additional, Grommes, C., additional, Panageas, K., additional, Reiner, A., additional, Barradas, R., additional, Abrey, L., additional, Gutin, P., additional, Lee, S. Y., additional, Slagle-Webb, B., additional, Glantz, M. J., additional, Connor, J. R., additional, Schlimper, C. A., additional, Schlag, H., additional, Stoffels, G., additional, Weber, F., additional, Krueger, D. A., additional, Care, M. M., additional, Holland, K., additional, Agricola, K., additional, Tudor, C., additional, Byars, A., additional, Franz, D. N., additional, Rice, L., additional, Chandler, J., additional, Levy, R., additional, Muro, K., additional, Nayak, L., additional, Norden, A. D., additional, Kaley, T. J., additional, Thomas, A. A., additional, Fadul, C. E., additional, Meyer, L. P., additional, Lallana, E. C., additional, Gilbert, M., additional, Aldape, K., additional, De Groot, J., additional, Conrad, C., additional, Levin, V., additional, Groves, M., additional, Chris, P., additional, Puduvalli, V., additional, Nagpal, S., additional, Feroze, A., additional, Recht, L., additional, Rangarajan, H. G., additional, Kieran, M. W., additional, Scott, R. M., additional, Lew, S. M., additional, Firat, S. Y., additional, Segura, A. D., additional, Jogal, S. A., additional, Kumthekar, P. U., additional, Grimm, S. A., additional, Avram, M., additional, Patel, J., additional, Kaklamani, V., additional, McCarthy, K., additional, Cianfrocca, M., additional, Gradishar, W., additional, Mulcahy, M., additional, Von Roenn, J., additional, Galanis, E., additional, Anderson, S. K., additional, Lafky, J. M., additional, Kaufmann, T. J., additional, Uhm, J. H., additional, Giannini, C., additional, Kumar, S. K., additional, Northfelt, D. W., additional, Flynn, P. J., additional, Buckner, J. C., additional, Omar, A. I., additional, Schiff, D., additional, Delios, A., additional, Jakubowski, A., additional, Melguizo-Gavilanes, I., additional, Qiao, W., additional, Wang, X., additional, Hashemi-Sadraei, N., additional, Bawa, H., additional, Rahmathulla, G., additional, Patel, M., additional, Elson, P., additional, Stevens, G., additional, Peereboom, D., additional, Vogelbaum, M., additional, Weil, R., additional, Barnett, G., additional, Ahluwalia, M. S., additional, Alvord, E. C., additional, Rockne, R. C., additional, Rockhill, J. K., additional, Rostomily, R., additional, Lai, A., additional, Wardlaw, J., additional, Spence, A. M., additional, Swanson, K. R., additional, Zadeh, G., additional, Alahmadi, H., additional, Wilson, J., additional, Gentili, F., additional, Beumer, J. J., additional, Wright, J., additional, Takebe, N., additional, Gaur, R., additional, Werner-Wasik, M., additional, Gupta, A. J., additional, Campos-Gines, A., additional, Le, K., additional, Arango, C., additional, Richards, M., additional, Landeros, M., additional, Juan, H., additional, Chang, J. H., additional, Kim, J. S., additional, Cho, J. H., additional, Seo, C. O., additional, Baldock, A. L., additional, Rockne, R., additional, Canoll, P., additional, Born, D., additional, Yagle, K., additional, Alexandru, D., additional, Bota, D., additional, Linskey, M. E., additional, Nabeel, S., additional, Raval, S. N., additional, Rosenow, J., additional, Bredel, M., additional, New, P. Z., additional, Plotkin, S. R., additional, Supko, J. G., additional, Curry, W. T., additional, Chi, A. S., additional, Gerstner, E. R., additional, Batchelor, T. T., additional, Hashemi, N., additional, Chao, S. T., additional, Weil, R. J., additional, Suh, J. H., additional, Vogelbaum, M. A., additional, Stevens, G. H., additional, Barnett, G. H., additional, Corwin, D., additional, Holdsworth, C., additional, Stewart, R., additional, Swanson, K., additional, Graber, J. J., additional, Anderson, A. R., additional, Jeyapalan, S., additional, Goldman, M., additional, Boxerman, J., additional, Donahue, J., additional, Elinzano, H., additional, Evans, D., additional, O'Connor, B., additional, Puthawala, M. Y., additional, Oyelese, A., additional, Cielo, D., additional, Blitstein, M., additional, Dargush, M., additional, Santaniello, A., additional, Constantinou, M., additional, DiPetrillo, T., additional, Safran, H., additional, Halpin, C., additional, Barker, F. G., additional, Maher, E. A., additional, Ganji, S., additional, DeBerardinis, R., additional, Hatanpaa, K., additional, Rakheja, D., additional, Yang, X.-L., additional, Mashimo, T., additional, Raisanen, J., additional, Madden, C., additional, Mickey, B., additional, Malloy, C., additional, Bachoo, R., additional, Choi, C., additional, Ranjan, T., additional, Yono, N., additional, Han, S. J., additional, Sun, M., additional, Berger, M. S., additional, Aghi, M., additional, Gupta, N., additional, and Parsa, A. T., additional

Published
2011
Full Text
View/download PDF

37. AT-17 * RE-ANALYSIS OF PFS/RESPONSE USING ORIGINAL MACDONALD CRITERIA AND RESPONSE EVALUATION CRITERIA IN SOLID TUMORS IN THE PHASE III AVAGLIO STUDY OF BEVACIZUMAB PLUS RADIOTHERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED GLIOBLASTOMA

Author

Chinot, O. L., primary, Wick, W., additional, van den Bent, M. J., additional, Mason, W., additional, Henriksson, R., additional, Saran, F., additional, Nishikawa, R., additional, Revil, C., additional, Kerloeguen, Y., additional, and Cloughesy, T., additional

Published
2014
Full Text
View/download PDF

42. ET-12 * PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Author

Cloughesy, T., primary, Finocchiaro, G., additional, Belda-Iniesta, C., additional, Recht, L., additional, Brandes, A. A., additional, Pineda, E., additional, Mikkelsen, T., additional, Chinot, O., additional, Balana, C., additional, Macdonald, D., additional, Westphal, M., additional, Hopkins, K., additional, Weller, M., additional, Bruey, J.-M., additional, Liu, B., additional, and Verret, W., additional

Published
2014
Full Text
View/download PDF

43. AT-02 * INTRATUMORAL DELIVERY OF THE RETROVIRAL REPLICATING VECTOR (RRV) TOCA 511 IN SUBJECTS WITH RECURRENT HIGH GRADE GLIOMA: INTERIM REPORT OF PHASE 1 STUDY (NCT 01156584)

Author

Aghi, M., primary, Vogelbaum, M. A., additional, Kesari, S., additional, Chen, C. C., additional, Liau, L. M., additional, Piccioni, D., additional, Portnow, J., additional, Chang, S., additional, Robbins, J. M., additional, Boyce, T., additional, Huang, T. T., additional, Pertschuk, D., additional, Ostertag, D., additional, and Cloughesy, T. F., additional

Published
2014
Full Text
View/download PDF

44. IT-05 * ADMINISTRATION OF TOCA 511 TO SUBJECTS WITH RECURRENT HGG UNDERGOING REPEAT RESECTION

Author

Cloughesy, T. F., primary, Kesari, S., additional, Kalkanis, S., additional, Mikkelsen, T., additional, Landolfi, J., additional, Elder, J. B., additional, Liau, L. M., additional, Chen, C. C., additional, Bloomfield, S., additional, Piccioni, D., additional, Chiocca, E. A., additional, Foltz, G., additional, Robbins, J. M., additional, Ostertag, D., additional, Jolly, D. J., additional, Ibanez, C., additional, Pertschuk, D., additional, Pan, C., additional, and Vogelbaum, M. A., additional

Published
2014
Full Text
View/download PDF

45. BI-10 * pH-WEIGHTED MRI IN HUMAN GLIOMAS

Author

Harris, R., primary, Cloughesy, T., additional, Liau, L., additional, Lai, A., additional, Nghiemphu, P., additional, Li, D., additional, Pope, W., additional, and Ellingson, B., additional

Published
2014
Full Text
View/download PDF

47. AT-18 * SURVIVAL ANALYSIS OF PATIENTS WITH A PFS EVENT WHO DID NOT RECEIVE POST-PROGRESSION THERAPY IN AVAGLIO (BEVACIZUMAB [BEV] PLUS RADIOTHERAPY [RT] AND TEMOZOLOMIDE [TMZ] FOR NEWLY DIAGNOSED GLIOBLASTOMA [GBM])

Author

Cloughesy, T., primary, Wick, W., additional, Mason, W., additional, Henriksson, R., additional, Saran, F., additional, Nishikawa, R., additional, Carpentier, A. F., additional, Hoang-Xuan, K., additional, Kavan, P., additional, Cernea, D., additional, Brandes, A. A., additional, Revil, C., additional, Abrey, L., additional, and Chinot, O. L., additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results